title: Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
abstract: BACKGROUND
  The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed.
  
  
  METHODS
  Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed.
  
  
  RESULTS
  The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2–94.4, p < 0.001) and disease-related mortality (95% CI, 2.2–163.9, p = 0.007).
  
  
  CONCLUSIONS
  The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.
authors.forename: Chi-An
authors.initials: CA
authors.lastname: Chen
authors.forename: Hao
authors.initials: H
authors.lastname: Lin
authors.forename: Chia-Sui
authors.initials: CS
authors.lastname: Weng
authors.forename: Kuo-Chang
authors.initials: KC
authors.lastname: Wen
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Lu
authors.forename: Hung-Hsueh
authors.initials: HH
authors.lastname: Chou
authors.forename: Yu-Fang
authors.initials: YF
authors.lastname: Huang
authors.forename: Chieh-Yi
authors.initials: CY
authors.lastname: Kang
authors.forename: Chih-Ming
authors.initials: CM
authors.lastname: Ho
authors.forename: Mu-Hsien
authors.initials: MH
authors.lastname: Yu
authors.forename: Cheng-Yang
authors.initials: CY
authors.lastname: Chou
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D059351:Organ Sparing Treatments; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin